Report contents
At a glance
- Business model: Intuitive Surgical sells da Vinci and Ion systems, then earns recurring instrument, accessory and service revenue as procedures run. Its installed base reached 12,094 systems in Q3 2026, up 12% year over year, and instruments and accessories produced $1.80 billion that quarter. Hospital capital committees control placement budgets; procedure growth, not placements, ultimately drives consumable pull-through.
- Financial quality: Operating cash flow exceeded net income from FY2021 through FY2025 and was 1.29 times net income in the June 2026 quarter. FY2025 free cash flow of $2.49 billion equaled 87% of net income; the balance sheet had no long-term debt and liabilities were 13% of assets. A heavier leased-system mix could delay cash collection without changing reported economics.
Business model
Business model: a capital sale that buys a decade of consumables
Intuitive Surgical sells robotic surgery to hospitals. The buyer is a hospital or health system that purchases a da Vinci or Ion system, pays for the single-use instruments and accessories each procedure consumes, and signs a service contract that keeps the machine in the operating room. The surgeon is the user, not the customer, and reimbursement from a public program or private insurer caps what the hospital can afford to pay. Pricing power therefore runs through a capital committee working from a fixed annual budget. Intuitive is a manufacturer in an expansion phase: the platform still reaches new procedure types and new countries, and the consumable tail attached to each installed system is long.
Where the profit sits
Three reported lines. Instruments and accessories are the largest and highest-margin, because every procedure consumes tools; that revenue tracks procedure volume and price and needs almost no incremental capital. Service is an annuity tied to the installed base and renewed under contract. Systems are the smallest line in most years and the lumpiest, since hospital capital budgets and the timing of a product launch decide how many get bought. Consolidated gross margin is high for a capital-equipment maker precisely because the recurring lines carry the profit, not the hardware.
The mix explains why headline growth can mislead. Revenue rose about 18% to $2.89 billion in the second quarter of 2026, but a placement-heavy quarter flatters the top line while adding comparatively little profit, and a quarter of strong procedures with weak placements can still deliver high-margin instrument revenue. The installed base reached roughly 11,400 systems at the end of the first quarter of 2026, up about 12% from a year earlier. Each of those is a claim on years of consumable purchases.
Disclosure is coarse. The filings split revenue into those three lines and into the United States versus the rest of the world. There is no separate Ion line, no procedure-level pricing, and no published figure for instruments consumed per case, so the razor-and-blade arithmetic has to be inferred from segment revenue divided by the disclosed installed base. Some systems also go out on operating leases or usage-based terms, converting a sale into a stream; the capital consequences of that shift belong with the cash-flow analysis, but the channel choice matters here because it lowers the entry cost for a hospital weighing a second vendor.
Procedures decide the outcome, placements only set capacity
Da Vinci 5 accounted for 315 of the 546 systems placed in the third quarter of 2026, against 240 of 427 a year earlier. Total placements rose as well, which suggests the launch is adding to the order book. What the mix does not settle is whether the new machines lift utilization or replace Xi systems hospitals would have used anyway. Procedure volume, not placement count, is the demand signal that matters.
Expansion comes from widening the set of operations performed robotically. Urology and gynecology remain the base; general surgery categories and thoracic work through Ion are where incremental cases have to come from, and each new category requires clinical evidence, surgeon training and, outside the United States, a reimbursement decision. That is slow work, and it explains why procedure growth has been a steadier series than system placements.
The advantage sits in training and case data, not hardware
The hardware is replicable; the accumulated evidence and the trained surgeons are not. Two decades of published outcomes across urology, gynecology and general surgery give a hospital committee a reason to stay on the platform, and Intuitive has trained surgeons to use it for years. A rival has to fund the same clinical and training work before it can bid credibly for a service line. That takes time, which is why the first competitor approvals read more as a change in negotiating conditions than as an immediate shift in share.
Bargaining power still runs through standardization. Once a hospital commits a service line to da Vinci, switching means retraining surgeons, rebuilding instrument inventory and renegotiating service coverage. Hospital buyers are consolidating, though, and they now have alternatives to place on a shortlist: Medtronic obtained FDA clearance for its Hugo system in urology in December 2025, and Johnson & Johnson filed its Ottava system for FDA review in the first quarter of 2026. Clearance is a negotiating fact before it is a commercial one, since a hospital can cite an approved second vendor in contract talks long before it moves volume.
What would change the judgment
The model holds while procedure growth stays in double digits and instrument spending per case does not erode. If procedures grow more slowly than the installed base for several quarters, capacity is being added faster than demand. Hospitals running two platforms in one service line without reducing da Vinci case volume would look like coexistence; the evidence that would overturn this view is a decline in procedures per installed system combined with flat or falling instrument revenue per procedure. Intuitive publishes neither figure, so the test has to be assembled from segment revenue and the disclosed base.
Questions worth following
- Do da Vinci 5 upgrades add procedures or just replace older systems?
Placement mix alone says little about demand if hospitals are trading in Xi systems they would have used anyway. If upgrades lift utilization, instrument revenue compounds on a base already paid for; if they are replacements, growth has to come from new accounts and new procedure categories.
- Will hospitals keep standardizing on da Vinci as rival robots arrive?
Standardization is the lock that keeps instrument and service revenue recurring. If hospitals begin running competing platforms inside a service line where da Vinci already operates, the installed base stops behaving like a captive annuity and contract talks get harder. Regulatory clearance alone would not settle it.
- Can Ion become a second recurring revenue engine?
Ion adds a bronchoscopy platform with its own catheters and service contracts. If it reaches scale, recurring revenue rests on two platforms instead of one and the growth runway extends past da Vinci procedures; if it stays small, the business remains tied to a single robot family.
Financial quality
Financial quality: elite returns, one pricing test
Intuitive Surgical's numbers are unusually clean for a device maker: a 28% net margin, mid-teens returns on equity with no debt, and operating cash flow that beat net income in every year from FY2021 through FY2025. Quality is not the issue. Durability is. Management now plans to charge less per procedure, and the margin structure has to absorb that without cracking.
Returns come from margins, not leverage
| USD bn unless stated | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Q2 FY2026 | Assessment |
|---|---|---|---|---|---|---|---|
| Revenue | 5.71 | 6.22 | 7.12 | 8.35 | 10.07 | 2.89 | Strong |
| Revenue growth (%) | 31.4 | 8.9 | 14.5 | 17.3 | 20.6 | 18.4 | Strong |
| Gross margin (%) | 69.3 | 67.4 | 66.4 | 67.5 | 65.9 | 67.8 | Strong |
| Operating margin (%) | 31.9 | 25.4 | 24.9 | 28.1 | 29.2 | 33.6 | Strong |
| Net margin (%) | 29.9 | 21.3 | 25.2 | 27.8 | 28.4 | 28.4 | Exceptional |
| ROE (%) | 15.7 | 11.5 | 14.8 | 15.6 | 16.7 | 4.6 | Strong |
| ROA (%) | 13.8 | 10.0 | 12.7 | 13.6 | 14.5 | 4.0 | Strong |
| Liabilities/assets (%) | 11.8 | 14.3 | 13.2 | 12.3 | 13.0 | 12.4 | Exceptional |
| Current ratio (x) | 5.08 | 4.40 | 4.76 | 4.07 | Not disclosed | Not disclosed | Strong |
| Capex | 0.35 | 0.53 | 1.06 | 1.12 | 0.54 | 0.11 | Adequate |
| Operating cash flow | 2.09 | 1.49 | 1.81 | 2.42 | 3.03 | 1.06 | Strong |
| Free cash flow | 1.74 | 0.96 | 0.75 | 1.30 | 2.49 | 0.95 | Strong |
| OCF/net income (x) | 1.22 | 1.13 | 1.01 | 1.04 | 1.06 | 1.29 | Strong |
| FCF/net income (x) | 1.02 | 0.73 | 0.42 | 0.56 | 0.87 | 1.16 | Adequate |
| Asset turnover (x) | 0.46 | 0.47 | 0.50 | 0.49 | 0.51 | 0.14 | Adequate |
*Single quarter. Revenue, cash flow and margins are not annualized; ROE, ROA and asset turnover are quarterly and not comparable to full-year figures.
FY2025 ROE of 16.7% and ROA of 14.5% sit almost on top of each other because liabilities are 13% of assets and long-term debt is nil (short-term borrowings were $0.04 billion). Nothing in the return comes from financial engineering. Equity grew from $11.04 billion at the end of FY2022 to $17.82 billion at FY2025, funded entirely by retained earnings.
Asset turnover near 0.5 is what keeps ROE below 20%. About one-sixth of the balance sheet is cash and investments, $3.37 billion at December 2025 and $2.76 billion at June 2026, earning a market yield. Strip that out and the operating business earns well above the consolidated 14.5% ROA. The franchise is more profitable than the headline, and idle cash is what dilutes it.
Cash conversion held while capex swung
| USD bn unless stated | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Assessment | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.25 | 2.44 | 2.50 | 2.87 | 2.77 | 2.89 | Strong | Improving |
| Operating income | 0.58 | 0.74 | 0.76 | 0.86 | 0.86 | 0.97 | Strong | Improving |
| Net income | 0.70 | 0.66 | 0.70 | 0.80 | 0.82 | 0.82 | Strong | Stable |
| Gross margin (%) | 64.7 | 66.4 | 66.4 | 66.2 | 66.1 | 67.8 | Strong | Improving |
| Net margin (%) | 31.1 | 27.0 | 28.0 | 27.9 | 29.6 | 28.4 | Strong | Stable |
| Total assets | 19.22 | 20.16 | 19.35 | 20.63 | 20.11 | 20.88 | Strong | Stable |
| Total liabilities | 2.01 | 2.21 | 2.31 | 2.69 | 2.51 | 2.58 | Exceptional | Stable |
| Cash | 2.57 | 3.40 | 2.81 | 3.37 | 2.04 | 2.76 | Strong | Mixed |
| Operating cash flow | 0.58 | 0.72 | 0.84 | 0.89 | 0.91 | 1.06 | Strong | Improving |
| Free cash flow | 0.47 | 0.56 | 0.74 | 0.73 | 0.81 | 0.95 | Strong | Improving |
Fiscal quarters, single-quarter figures. Net PP&E is not disclosed for these periods.
Operating cash flow divided by net income never fell below 1.01: 1.22, 1.13, 1.01, 1.04 and 1.06 from FY2021 to FY2025, and 1.29 in the June 2026 quarter. Reported profit is cash-backed. Free cash flow conversion tells a different story. FCF/net income went from 1.02 in FY2021 to 0.42 in FY2023 and 0.56 in FY2024 before recovering to 0.87. That dip was capital spending, not accounting: capex reached $1.06 billion and $1.12 billion in those two years, 15% and 13% of revenue, against $0.54 billion, or 5.4%, in FY2025.
The money went into leased systems, instruments and facilities. ROA rising from 12.7% in FY2023 to 14.5% in FY2025 says the spending has not yet diluted consolidated returns. If leases become a larger share of placements, capex will track revenue again and FCF conversion will spend more time below 1. Free cash flow of $2.49 billion against $2.86 billion of net income in FY2025 is a strong outcome that depends on the lease mix staying where it is.
The instrument price cut is the test
On its October 20 call, management said pricing changes will cut instrument revenue per procedure by about 3% to 5% once fully in place, rolling out country by country from the first half of 2027. The changes include a China billing-code revision from November, longer-life instruments and lower prices aimed at high-volume procedures such as hernia repair. Instruments and accessories are the recurring, highest-margin line in the business, so the cut lands close to gross profit. Management's offsets are procedure growth guided at 14% to 15% for 2026, mix toward da Vinci 5 and SP that lifts revenue per procedure, and lower product costs, which raised 2026 adjusted gross margin guidance to 68.7%–69.3%.
Reported gross margin has stayed inside a 65.9%–69.3% band for five years and was 67.8% in the June 2026 quarter. A 3%–5% price cut is roughly the size of the entire four-year drift in that band. The evidence so far shows a stable margin, not a deteriorating one; the 2027 rollout is what would separate a temporary pricing investment from a structural reset.
What to check
- Instrument revenue per procedure against gross margin. The company discloses revenue per procedure each quarter. A decline inside the guided 3%–5% with gross margin near 66% means mix and cost savings are absorbing it. A larger decline, or gross margin below roughly 65%, means the price cut is reaching profit.
- Buybacks against free cash flow. Financing outflows were $2.36 billion in FY2025, close to the $2.49 billion of free cash flow, but $1.35 billion in the March 2026 quarter alone against $0.81 billion of FCF, which took cash from $3.37 billion to $2.04 billion before it recovered to $2.76 billion. Trefis put the shares at 51 times trailing earnings on October 30, 2026; repurchases at that multiple are a bet on continued growth as much as a return of capital.
- Working capital. Inventory turnover slipped from 2.27 in FY2022 and FY2023 to 2.01 in FY2024 as inventory rose 22% against 17% revenue growth. Receivable days have held between roughly 50 and 65. Inventory of $1.67 billion and receivables of $1.39 billion were last broken out at June 2025, so whether faster 2026 growth is being pulled forward by credit terms or channel stocking will be clearest in the next annual filing.
- One-off items in the tax line. Q1 2025 net income of $0.70 billion exceeded operating income of $0.58 billion because the tax provision was a $0.03 billion benefit, so quarterly net margins move on tax as well as operations. Operating income is the cleaner read: it rose from $0.74 billion in Q2 2025 to $0.97 billion in Q2 2026.
Questions worth following
- Can Intuitive protect gross margin as instrument prices fall in 2027?
A 3% to 5% cut in instrument revenue per procedure lands mostly on gross profit, since instruments and accessories carry the highest margin. If procedure growth and product mix do not offset it, the earnings base that funds buybacks and leased-system investment shrinks.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Key risksWhat could break the investment case
- Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
- SummaryOur overall judgement and what to watch next
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Intuitive Surgical Inc
Intuitive Surgical Inc
Business, moat and key questions
Open company page